about
Centaurin beta1 down-regulates nucleotide-binding oligomerization domains 1- and 2-dependent NF-kappaB activationMild clinical behaviour of Crohn disease in elderly patients in a Latin American country: A case-control studyPharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategiesRole of the HLA-DQ locus in the development of chronic gastritis and gastric carcinoma in Mexican patients.Perinuclear anti-neutrophil cytoplasmic antibodies (p-anca) in chronic ulcerative colitis: experience in a Mexican institution.Association of the HLA-DRB1*0701 allele with perinuclear anti-neutrophil cytoplasmatic antibodies in Mexican patients with severe ulcerative colitisTranscript levels of Toll-Like Receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis.Basic and clinical aspects of osteoporosis in inflammatory bowel disease.Crohn's disease: innate immunodeficiency?Association of HLA-DRB1*16 with chronic discoid lupus erythematosus in Mexican mestizo patients.Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis.Evaluation of diet pattern related to the symptoms of mexican patients with Ulcerative Colitis (UC): through the validity of a questionnaireDifferential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis.Innovative therapeutics for inflammatory bowel diseaseInnate immunity in inflammatory bowel disease.Genetic factors associated with the development of inflammatory bowel disease.Indoleamine 2,3-dioxygenase: expressing cells in inflammatory bowel disease-a cross-sectional study.Immunoregulatory Pathways Involved in Inflammatory Bowel Disease.Genetic Markers Associated with Clinical Outcomes in Patients with Inflammatory Bowel Disease.The Mexican consensus on probiotics in gastroenterology.Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part).Genetic polymorphisms of interleukin-22 in patients with ulcerative colitis.Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis.High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis.High gene expression of CXCL8 is associated with the presence of extraintestinal manifestations and long-term disease in patients with ulcerative colitis.Polymorphisms in the promoter region of tumor necrosis factor alpha (TNF-alpha) and the HLA-DRB1 locus in Mexican mestizo patients with ulcerative colitis.Expression of HNF4γ is downregulated in patients with active ulcerative colitis (UC) compared to UC patients in remission and healthy controls.Clinical epidemiology of ulcerative colitis in Mexico: a single hospital-based study in a 20-year period (1987-2006).HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis.Genetic polymorphisms of interleukin 20 (IL-20) in patients with ulcerative colitis.Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.IL-10-- and IL-20--expressing epithelial and inflammatory cells are increased in patients with ulcerative colitis.Joint involvement in Mexican patients with ulcerative colitis: a hospital-based retrospective study.[Infection frequency in patients with chronic idiopathic ulcerative colitis].Effect of Cis-palmitoleic acid supplementation on inflammation and expression of HNF4γ, HNF4α and IL6 in patients with ulcerative colitis.Intestinal protozoa infections among patients with ulcerative colitis: prevalence and impact on clinical disease course.HLA-DRB1 alleles are associated with the clinical course of disease and steroid dependence in Mexican patients with ulcerative colitis.Frequency, Clinical Features and Factors Associated with Pouchitis after Proctocolectomy with Ileo-Pouch-Anal Anastomosis in Patients with Ulcerative Colitis: A Latin-American Country Retrospective-Cohort Study.Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico.The Mexican consensus on the diagnosis and treatment of ulcerative colitis.
P50
Q28265688-9F9498EB-ECA2-4643-93B1-37B1226B99B6Q30384926-4006C3CB-6AF7-4A6C-97EE-9EEF82E0D9D3Q33758469-13B0A7CC-574C-404F-A321-AADF0D171E71Q33866675-3EF775FC-B664-4156-823F-B4FE86B1E378Q33867983-7A26CAF5-413A-4B0B-AF1B-071DB69E28A1Q34012623-8B3DD9ED-231E-4793-AC45-3A4EA3BC749CQ34106945-49D958F0-DE24-4A1D-8462-9D9B3AD05FA0Q34225188-BB4691AF-B13B-46FA-80BD-495811885E2CQ34581819-8FDD98FE-A434-47EB-8815-1DAEBE49FFD9Q34610859-FE06EB6D-70E6-48B1-801E-DCA40D806447Q34762999-441FE1B3-48D7-4153-8A9D-0775F550A21AQ35225660-22F04919-5D5C-4415-8017-0DA53CE2E277Q36386677-D316C2D5-5988-4D03-B435-FB21D0A1605EQ36802524-33F15F70-5658-44B3-94B1-B614A9B2543FQ36975932-92BEC358-64EB-4B7A-8891-57E1D048A601Q36975937-4CA3A406-EBB6-4BE0-B7E4-79205738CF37Q37301247-731AED4F-C651-4072-8436-E86C6DE6490DQ38537820-1E53380F-8709-4E3C-A280-3987126B2070Q38561218-F3E02752-6FEB-498E-AB0E-7F247F7C27A1Q39095486-26580015-69E3-4B08-9076-26914EC24C7FQ40288106-22B51DFA-EF3D-4BB1-8243-C7DB6E691703Q40844037-8186402B-ED09-4D1A-AE3F-07DD26660116Q40893341-8302F57D-A677-4E42-896E-E892728AF074Q43284329-9D1D4209-E932-4B7C-924A-55EAAB632CCDQ43596057-325D5D20-3B04-45DA-966E-2EBFBCAF309EQ43656662-298B5940-4395-4281-88BD-5927B66691BCQ43902124-42C4BE9A-C748-44CC-AC0F-E74C44DFBCB2Q44216164-AE36DE04-EEF8-4EF5-A340-81F6F14145C3Q44670945-CA6BB534-22F3-4EDF-BFE6-647E6FFA4556Q46122588-2467DBA9-3CB6-49A0-842D-0724B973964CQ46250193-4272A65E-2217-496E-A6F6-E8B389AD3EC7Q46676392-C50C6552-187D-4878-A0E7-352343C0F15AQ47638016-F27F3F44-57C9-4EA0-B180-B40DEB199378Q50021041-0C9E17B4-CB5B-43F5-800E-511892A6719CQ51142675-29F6A3EA-D2EE-4158-AE7B-252F63FEE0FAQ51584230-E0BD848A-914E-4FAB-B76A-7FCED6871837Q51620687-BDCB6C39-5D6D-4920-94F1-6D47BE1E7F98Q51628815-D21CB1A4-F99B-4724-89D9-F99CE489C42FQ52568836-C74CDBF3-C0D5-4B30-8ACE-0EC2A0871EFEQ52675195-55897935-91DD-432F-A57C-4598E817CBD0
P50
description
researcher ORCID ID = 0000-0002-5247-5812
@en
wetenschapper
@nl
name
Jesus Yamamoto-Furusho
@ast
Jesus Yamamoto-Furusho
@en
Jesus Yamamoto-Furusho
@es
Jesus Yamamoto-Furusho
@nl
type
label
Jesus Yamamoto-Furusho
@ast
Jesus Yamamoto-Furusho
@en
Jesus Yamamoto-Furusho
@es
Jesus Yamamoto-Furusho
@nl
prefLabel
Jesus Yamamoto-Furusho
@ast
Jesus Yamamoto-Furusho
@en
Jesus Yamamoto-Furusho
@es
Jesus Yamamoto-Furusho
@nl
P106
P1153
6602490769
P31
P496
0000-0002-5247-5812